Positive Impact of Implementing a Comprehensive Genetic Testing Protocol for Prostate Cancer Patients in a Multi-disciplinary Uro-oncology Practice. Letter.

Abstract

You have accessUrology PracticeLetters to the Editor1 Mar 2023Positive Impact of Implementing a Comprehensive Genetic Testing Protocol for Prostate Cancer Patients in a Multi-disciplinary Uro-oncology Practice. Letter. Siddharth Ramanathan, Andrew Korman, Howard Korman, and Savitha Balaraman Siddharth RamanathanSiddharth Ramanathan * E-mail Address: [email protected] Oakland University William Beaumont School of Medicine, Rochester, Michigan Comprehensive Urology, Rochester, Michigan More articles by this author , Andrew KormanAndrew Korman Comprehensive Urology, Rochester, Michigan More articles by this author , Howard KormanHoward Korman Comprehensive Urology, Rochester, Michigan More articles by this author , and Savitha BalaramanSavitha Balaraman Michigan Healthcare Professionals Hematology & Oncology, Rochester, Michigan More articles by this author View All Author Informationhttps://doi.org/10.1097/UPJ.0000000000000383AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail Urol Pract. 2023;10(1):33-39. To the Editor: It has been well documented that patients harboring specific germline mutations are at increased risk of prostate cancer, often as part of broader syndromes such as hereditary breast and ovarian cancer or Lynch syndrome. An estimated 16% of patients with metastatic prostate cancer possess mutations in the BRCA genes. BRCA2 mutations have a stronger association with prostate cancer than BRCA1 mutations, and carriers of BRCA2 mutations also tend to have more aggressive malignancy with poorer prognosis.1 Additionally, preliminary studies suggest that BRCA2 carriers have a significantly higher likelihood of prostate cancer progression during active surveillance.2 However, there is less evidence regarding the management of patients with actionable mutations in the nonmetastatic setting, likely due to a significant lack of data on the subject. As such, we believe this study presents a unique solution by outlining a successful model for providing genetic testing to prostate cancer patients.3 Certainly, as noted, barriers to implementation will be encountered and the uncertainty regarding the optimal management of genetic mutations in patients with nonmetastatic cancer may persist. However, we believe that the implementation of a comprehensive genetic testing workflow can pave the way to answer many of these questions. Potentially, as more data become available on other successful genetic testing protocols, the barriers to implementation will be commensurately reduced. It is our hope that, through the introduction of genetic testing on a larger scale, a greater number of actionable mutations are identified and health care providers may gain a greater understanding regarding the management of nonmetastatic prostate cancers with pathogenic mutations. REFERENCES 1. . Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol. 2013; 31(14):1748-1757. Crossref, Medline, Google Scholar 2. . Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer. Eur Urol. 2015; 68(2):186-193. Crossref, Medline, Google Scholar 3. Positive impact of implementing a comprehensive genetic testing protocol for prostate cancer patients in a multi-disciplinary uro-oncology practice. Urol Pract. 2023; 10(1):33-39. Google Scholar Submitted December 9, 2022; accepted December 9, 2022; published 000. © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 10Issue 2March 2023Page: 111-111 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Siddharth Ramanathan Oakland University William Beaumont School of Medicine, Rochester, Michigan Comprehensive Urology, Rochester, Michigan * E-mail Address: [email protected] More articles by this author Andrew Korman Comprehensive Urology, Rochester, Michigan More articles by this author Howard Korman Comprehensive Urology, Rochester, Michigan More articles by this author Savitha Balaraman Michigan Healthcare Professionals Hematology & Oncology, Rochester, Michigan More articles by this author Expand All Submitted December 9, 2022; accepted December 9, 2022; published 000. Advertisement Advertisement PDF downloadLoading ...